Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...

We are witnessing a long-awaited transformation in depression care. After decades of incremental change, new therapeutic ...

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease ...

At its second attempt, Rocket Pharma has won FDA approval for its gene therapy for severe leukocyte adhesion deficiency type ...

Merck KGaA has teamed up with Flagship Pioneering's Valo Health on an ambitious project to apply AI to the discovery of novel drug targets and therapeutics for Parkinson's disease. The partnership ...

Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion. If the $12.50-per-share all-cash deal is completed, it will give ...

"Screening is typically recommended for patients with confirmed liver cirrhosis or severe liver disease, since many cases of ...

Every clinical trial is built on the promise that the risk is justified by the strength of the evidence supporting it.

The data reveal from the phase 1 INLIGHT study of WVE-007 – an oligonucleotide-based gene-silencing drug designed to switch ...

With the ink barely dry on one takeover agreement, Novartis has signed another, promising to pay up to $2 billion to acquire ...

The GLP-1 market is huge and growing, and depending on how patients acquire and pay for their therapies, traditional data ...

What is less often examined is how healthcare professionals actually experience survey design, and where common research ...